disappointment the recurrent and late cases they are asked to treat, with the majority deriving little benefit; Even those patients showing a response are unlikely to be cured because they have metastatic disease, though response of local lesions may be quite good.
The aim of this paper is to try to assess the value of radiotherapy as a curative form of treatment. The first group of patients I wish to discuss are those with malignant melanoma of the skin. Between 1943 and 1952 there were 165 patients having their prigiary treatment at the Christie Hospital, who were diagnosed as having malignant melanoma. Sixty-three patients had surgical excision and histologically proved disease, and of these, 38 survived five years. Seventy-eight patients were treated by radiation, most of them without histological confirmation, which was not obtained as the prevailing policy was to treat without biopsy any suspicious pigmented lesion. Biopsy was considered to be dangerous leading to dissemination and death. Most but not all of the survivors in this group of 49 probably had pigmented basal cell carcinoma, though experience of 6 patients who had a biopsy before radiation suggests that, as 2 survive, some of the cases without histological proof were cured of malignant melanoma. A larger group of patients seen between 1945 and 1966 with histologically proved melanoma treated by radiation, shows that 10 out of 31 survive at five years; so that approximately a third are cured. There were 16 patients whose lesions did not respond to radiation in the first period and after subsequent surgery 9 survived nine years, so that the policy of treating with radiation without biopsy did not make subsequent surgery any less successful in the nonresponders.
Malignant melanoma, in and around the orbit, seems to have a better prognosis with radiation. Even on the eyelids as Halnan reported in 1962, 3 of 5 patients with malignant melanoma of the eyelid survived five years, all being histologically proven. Lesions of the uveal tract are usually treated by removal of the eye and radiotherapy is mainly used in patients with locally residual or recurrent tumours. Thirteen such patients were reviewed by Halnan and 6 survived five years. In 9 of the patients the disease was confined to the orbit at the time of radiation and 5 survived five years; a much better result than when spread had occurred beyond the orbit.
Malignant melanoma may arise on the limbus but this is rare and not many series have been reported. Lederman (1952) reported good results with local surgery and threaded radon seeds delivering 3000-4000 R in three to four days.
Between 1945 and 1966 there were a total of 24 patients with malignant melanoma arising in the nose, sinuses, mouth and pharynx and larynx, and only one patient survives. During the same period 8 patients had a surgical excision and none survived. One further case treated since 1966 will probably survive five years and this illustrates how long it may be before complete regression takes place. This patient had a malignant melanoma of the left upper alveolus and left submandibular lymph gland. The primary was given 5500 rads in three weeks using a 4 MeV linear accelerator and the node received 5000 rads from a 300 kilovolt tube in the same time. The primary regressedwvery slowly and was completely healed twenty months after treatment. At this time, the lymph node which had regressed partially was thought to be growing again and was therefore excised. Histologically, it was invaded by malignant melanoma. The patient remains well 4j years after her initial treatment. Failure to cure in this group was often from distant metastases although in many instances the local disease was controlled. It seems to me from the results I have quoted that radiation is second best to surgery in the curative treatment of malignant melanoma of the skin, although it obviously has a place in situations where surgery is not applicable and may succeed in cure, and certainly in a good remission of symptoms. In other sites as in the uveal tract, it will produce a considerable number of cures, and should always be considered if surgery fails. In lesions of the mouth, sinuses, nose and pharynx, whilst cures may be unlikely as distant metastases are nearly always present, occasional cure results and good palliation is achieved in terms of local control.
Mr J M Edwards (St Thomas' Hospital Medical School, London SEI)

Treatment of Melanoma by
Endolymphatic Therapy
Endolymphatic therapy for melanoma is concerned with treatment ofmetastases in the regional lymph nodes. For effective therapy the lymph nodes in the direct lymphatic pathway from the melanoma should be infused. The nodes should contain metastases small enough to be destroyed by the isotope.
The material most commonly used for this type of treatment is 32P-Lipiodol. Apart from the therapeutic component, this combination is also radiopaque which allows diagnostic assessment of the lymph node condition. The techniques applied are:
Treatmentfor Stage I Melanoma For Stage 1 melanoma (primary melanoma, lymph node clinically negative) the development of lymph node metastases should be eradicated by the correct application of endolymphatic therapy. It is known that, although apparently uninvolved, the lymph nodes contain small metastases in up to one-third of cases. These metastases are of such dimensions that they would be destroyed by the isotope used. (The mean penetration in tissue of 32P is 4 mm.)
Following the excision of the primary melanoma, and with pathological confirmation of a truly invasive lesion, preparation is made for treatment, ideally within a two to three week period. The technique of therapeutic lymphography is a modification of the diagnostic technique which is now well known (Kinmonth et al. 1955a (Kinmonth et al. , 1955b . The main modifications are those concerning protection and safety because of the use of radioactive materials. The aims are to ensure adequate filling of the regional nodes likely to be involved with metastatic disease, without undue spillover of radioactive material to the lung fields via the thoracic duct or other lymphovenous connections (Edwards & Kinmonth 1968 , Edwards 1969 .
Whenever possible, injection of the radioisotope combinations is made just proximal to the excision area of the melanoma into lymphatics which would have been traversed by malignant cells. Occasionally infusion of the isotope is made from two sites to cover a wider field. The lymphatics are demonstrated by the subcutaneous injection of patent blue violet (10% aqueous solution). Cannulation is made using a No. 30 gauge needle set with subsequent slow infusion of the isotope. The procedure is carefully monitored by early radiography of the limb and regional node areas. In addition, external scanning of the patient, using a collimated Geiger counter enables the progress of the radioactive material to the nodes to be followed. Warning may be given of the presence of lymphovenous connections, which rarely occur but may develop in tumour-disorganized lymph nodes. The injection is stopped when the radioactive material has filled the proximal group of lymph nodes.
After the procedure the patient usually remains in hospital for five days. Further radiographs are taken 24 hours after infusion to examine the lymph nodes in detail (lymphadenograms). The X-rays are obtained in two or three separate projections and examined for filling defects which may suggest larger metastases. Usually in Stage 1 disease no suspicious filling defects indicating gross metastatic disease are shown. Obvious lymph node disease would require surgical excision for complete eradication, as the limited f-particle penetration would not guarantee destruction of such nodes. The patients are also scanned in the postoperative period by means of a Picker magna scanner. Measurements of radioactivity over the nodes are made. The spillover to the lungs is usually below .5 % and has caused no complications over the fifteen years that the technique has been used.
Treatmentfor Stage 2 Melanoma Stage 2 melanoma (primary melanoma, regional nodes clinically involved) represents a much more serious problem. It is recognized universally that the prognosis is very much worse than in Stage 1 disease. Following endolymphatic therapy, a surgical block dissection is performed after radioactivity has decayed to a safe level, usually after six weeks. Possible advantages in combining endolymphatic therapy with surgery for this stage are: (1) Implantation of viable cells at site of surgery may be reduced; (2) The effective limit of treatment may be extended by treating proximal lymph nodes which are not included in the usual limits of block dissection; (3) Operative radiography aids completeness of block dissection; (4) Diagnostic information of occult disease may be provided.
Results
Since 1958, when endolymphatic therapy was initiated at St Thomas' Hospital (Jantet et al. 1964 ) some 189 patients have been treated using this technique. The overall survival rate for Stage 1 and 2 disease has been 70%. For Stage 1 the crude survival rate is 87 % and 41 % for Stage 2.
The five year survival rate for Stage 1 is 80% and for Stage 2 it is 21.4%.
The relatively poor results for Stage 2 reflect the probability that patients with manifest lymph node disease have already a systemic problem at the time of endolymphatic therapy. The localized disease is usually eradicated, but deaths occur from the systenic manifestations. The Medical Research Council trial on melanoma which compares our technique of treatment with other methods may indicate the value of endolymphatic therapy. This trial, which we helped to instigate, is the first on a national scale to group together large series of melanoma patients. The early results of the trial are now being analysed.
It must be recognized that there are certain problems with endolymphatic therapy when applied on a larger scale:
(1) The technique of therapeutic lymphography is occasionally difficult. In some cases it may be necessary to give multiple injections in order to fill nodes adequately, which can be difficult for the occasional operator.
(2) Distribution of the isotope in the node is not always homogeneous, a condition essential for complete destruction of metastases. Other isotopes such as radioactive yttrium, with a longer range ,8-particle, or a combination of different isotopes may obviate the occasional patchy distribution.
More work is needed in these aspects of endolymphatic treatment, and this must be done in specialized centres. Approximately 500 people in England and Wales die each year of malignant melanoma. Treatment by chemotherapeutic limb perfusion (Ryan et al. 1957 , Creech et al. 1958 ) subsequent to wide excision and grafting with or without block dissection is widely practised in North America, but there are no longterm results published of such treatment in this country. This paper analyses experiences with this therapy in the Surgical Unit at St Mary's Hospital where, for the last thirteen years, it has been used for patients with malignant melanoma.
Method
The affected limb is isolated by a tourniquet and the main artery and vein are cannulated. An extracorporeal circuit containing a pump oxygenator is used. The cytotoxic agent used is 1-phenylaline nitrogen mustard in a dose of 1-2 mg/kg body weight in divided doses over 40-105 min. A crude estimate of the systemic leak of the drug is obtained by using a radioactive tracer in the perfusion circuit. Block dissection is then performed where indicated.
Clinical Material
Patients were selected for perfusion if the primary lesion was invasive, using the histological classification of Lloyd (1962) , and if full investigation had indicated that the primary or recurrent tumour was confined to one limb. There were 56 patients in all, 14 men and 42 women; 50 underwent one perfusion, 5 patients had 2, and 1 had 3. They were grouped as follows: (1) Primary invasive melanoma treated by wide excision and grafting, perfusion and bloc dissection. (2) Recurrent melanoma treated by wide excision, grafting and perfusion. (3) Recurrent melanoma treated by perfusion alone because of extensive local disease.
Complications
The complications of the operation are summarized in Table 1 . The thrombosed femoral artery was diagnosed at the time of the second perfusion, ten months after the initial treatment; short occlusion was found but peripheral pulses were present and there was no history of claudication. The incidence of local wound complications has been reduced in the last 13 patients by using a medially based skin flap when performing bloc dissection. The neuritis and vasomotor changes in the hand were in the same patient and recovery was complete. Leukopenia was defined as a drop in white cells below 4000/mm3; these 3 patients were treated in an isolation ward and did not develop any infections.
Results
Of the 56 patients perfused, 43 were available for a five-year survey. Of these 43, 29 patients survived five years, giving an overall figure of 67% (36 women and 7 men). Results in our three groups were as follows:
Group 1: Of 16 patients with primary invasive limb melanoma, 11 survived five years. Twelve patients had inguinal or axillary nodes free of 
